Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Orphazyme announces participation in upcoming virtual investor conferences
ORPHAZYME A/SFebruary 26, 2021 GMT
Orphazyme A/S Company Registration No. 32266355
Copenhagen, Denmark and Chicago, IL, February 26, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that Anders Vadsholt, interim CEO and CFO of Orphazyme, will be participating in the following upcoming investor conferences:
ADVERTISEMENT
Cowen Healthcare Conference, March 1-3, 2021:
Panel discussion moderated by Cowen analysts Phil Nadeau, Ritu Baral and Boris Peaker entitled “New Drug Launches Panel” on Wednesday, March 3, 2021 from 10:20-11:20 AM EST
Operator
Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter and Full Year 2020 Financial Results Call. Please be advised that today s call is being recorded.
I would now like to hand the conference over to your host for today, Chau Cheng, CytomX s Vice President, Investor Relations and Corporate Communications. Please go ahead.
Chau Cheng
Vice President, Investor Relations and Corporate Communications
Thank you, Victor. Good afternoon, and thank you for joining us. With me today are Dr. Sean McCarthy, CytomX s President, Chief Executive Officer and Chairman; Dr. Amy Peterson; Chief Development Officer; and Carlos Campoy, Chief Financial Officer. Earlier today, we issued a press release that includes a summary of our fourth quarter and full year 2020 financial and highlights the important progress we made during the year. We encourage everyone to read today s press release and the associated materials, which have
Operator
Good morning and welcome to ImmunoGen s Fourth Quarter and Full-Year 2020 Financial and Operating Results Conference Call. Today s conference is being recorded.
At this time, I would like to turn the call over to Courtney O Konek, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Courtney O Konek
Senior Director of Corporate Communications and Investor Relations
Good morning, and thank you for joining today s call. Earlier today, we issued a press release that includes a summary of our recent progress and fourth quarter and full-year 2020 financial results. This press release and a recording of this call can be found under the Investor and Media section of our website at immunogen.com.